Browsing by Author "Fonseca, P"
Now showing 1 - 7 of 7
Results Per Page
Sort Options
- Antiangiogénicos na Degenerescência Macular Relacionada com a Idade: a medicina baseada na evidência e a utilização off-labelPublication . Faria de Abreu, JR; Silva, R; Cachulo, ML; Figueira, J; Pires, I; Fonseca, P; Murta, JN
- Long-term follow-up of myopic choroidal neovascularization treated with ranibizumabPublication . Franqueira, N; Cachulo, ML; Pires, I; Fonseca, P; Marques, I; Figueira, J; Silva, RPURPOSE: To evaluate the long-term safety and efficacy of intravitreal ranibizumab in the treatment of myopic choroidal neovascularization (CNV). METHODS: Three-year retrospective, nonrandomized, interventional case series. Forty eyes of 39 patients with myopic CNV were included; 15 with previous photodynamic therapy, and 25 naïve eyes. Best-corrected visual acuity (BCVA) changes, central foveal thickness (CFT), and number of treatments were assessed, from baseline to month 36. RESULTS: Mean visual acuity improved from 55.4 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline to 59.7 letters at 12 months (p = 0.07), 61.8 letters at 24 months (p = 0.008) and 63.4 letters at 36 months (p = 0.039). Twenty-five percent of the patients gained ≥15 letters (3 lines) at 12 months, 30% at 24 months and 35% at 36 months. There was a mean reduction of 80 μm in CFT (p < 0.001). A mean of 4.1 injections were performed in the first year, 2.4 in the second year and 1.1 in the third year. Fifty-three percent of the eyes had no need for treatment during the third year of follow-up. CONCLUSIONS: Intravitreal ranibizumab seems to be an effective and safe therapeutic procedure to treat CNV in highly myopic eyes, with a high proportion of patients gaining or stabilizing BCVA at a 3-year follow-up.
- MÓDULO 2 - 2º Curso de Formação para Internos 2013 - 2014:Pediatria AmbulatóriaPublication . Bento, C; Rodrigues, F; Oliveira, G; Lopes, MF; Brito, MJ; Oliva, M; Dinis, I; Correia, AJ; Soares, R; Fonseca, P; Ramos, L; Mirante, A
- MÓDULO 2 - Pediatria do Ambulatório IPublication . Bento, C; Rodrigues, F; Oliveira, G; Lopes, MF; Brito, MJ; Canha, J; Oliva, M; Fonseca, P; Soares, R; Lemos, S
- Rastreio auditivo neonatal universalPublication . Fonseca, P; Ramos, C
- Terapêutica Fotodinâmica no tratamento da Coriorretinopatia Serosa Central Crónica: 4 anos de seguimentoPublication . Gregório, T; Pires, I; Cachulo, ML; Figueira, J; Fonseca, P; Santos, AR; Oliveiros, B; Silva, R
- Treatment of exudative age-related macular degeneration with intravitreal ranibizumab in clinical practice: a 3-year follow-upPublication . Marques, I; Fonseca, P; Luz Cachulo, M; Pires, I; Figueira, J; Faria de Abreu, JR; Silva, RPURPOSE: To evaluate the 36-month efficacy of intravitreal ranibizumab injections for choroidal neovascularization secondary to age-related macular degeneration (AMD) in real world clinical practice. METHODS: Retrospective study involving 84 eyes of 77 patients; 52 eyes completed 3 years of follow-up. Subjects were observed initially on a monthly basis and with extended follow-up intervals if signs of quiescence were detected, according to an established protocol. A comprehensive ophthalmologic examination was performed, including best-corrected visual acuity (BCVA) determined with Early Treatment Diabetic Retinopathy Study charts, stereoscopic macular biomicroscopy and optical coherence tomography (OCT) with fluorescein angiography and indocyanine green angiography if considered necessary. Treatment was given if signs of active lesions were present. RESULTS: The mean baseline BCVA was 49.33 and 49.52 letters at the 36-month visit. The average of treatments was 8.6 at 3 years. At this time point, 77% of treated eyes stabilized or improved their vision (VA loss ≤ 5 letters). A predictive value for better VA was found for younger age, better baseline VA, good response on OCT and more frequent treatments. CONCLUSION: At 3 years, intravitreal ranibizumab is able to maintain baseline VA in exudative AMD patients, with a reduced number of injections, but not to show VA improvement, in clinical practice.